Leave us alone on healthcare service provision, UK tells EC:
This article was originally published in Clinica
There are growing concerns about the way in which the proposed EU Services Directive could impact healthcare provision at the national level. In the UK, the British Medical Association is calling for healthcare to be excluded from the scope of the Directive as it fears that there could otherwise be a lowering of standards among doctors in the UK and too much of a business orientation in the provision of healthcare. It is said to have the support of UK government ministers and of governments in other countries too. Although the European Commission claims that it does not intend to tell countries how to run their health services, it is proposing under the Directive that member states would need to justify any proposed changes to their health service rules, and prove them to be "non-discriminatory, necessary or proportional." The BMA is to lobby MEPs on this issue ahead of a public hearing on the proposed Directive, scheduled for November 11 in Brussels.
You may also be interested in...
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.
Perrigo will launch generics of GSK's OTC Voltaren Arthritis Pain drug later in 2020 following FDA approval of its ANDA. GSK, which received FDA's OTC switch approval in February, still hasn't launched the product or indicated when it will.
Kline & Company’s worst-case scenario – which it says is looking more and more likely – has the US cosmetics and personal-care market declining by as much as 8.1% in 2020. However, Kline, Mintel and other market intelligence firms say there are opportunities available to companies struggling to weather the COVID-19 storm.